Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
- Novo: 6 events in the last 90 days
- Previous: 7 days earlier · After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company’s stock soaring
What happened
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
Summary assembled by rule from the sources below